NCT06302621 - Pemigatinib + Afatinib in Advanced Refractory Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 17, 2024

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2027

Conditions

Advanced Solid TumorUnresectable Solid TumorMetastatic Solid TumorCholangiocarcinoma

Interventions

DRUG

Afatinib

Each study treatment cycle lasts 21 days: Afatinib, oral, once daily, per protocol determined number of days per cycle and per protocol determined dosage

DRUG

Pemigatinib

Each study treatment cycle lasts 21 days: Pemigatinib, oral, once daily, per protocol determined number of days per cycle and per protocol determined dosage

Trial Locations (1)

02115

RECRUITING

Massachusetts General Hospital, Boston